• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human ASB2 Polyclonal Antibody

The antibody against ASB2 was raised in rabbit using the Fusion protein of Human ASB2 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, IHC.

ADC-30547A

The antibody against ASB2 was raised in rabbit using the Fusion protein of Human ASB2 as the immunogen. This antibody exists as a non-conjugated isotype IgG, Antigen affinity purified. This antibody has been validated on ELISA, IHC.

$299.00

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADC-30547A ClonalityPolyclonal
Host SpeciesRabbitTarget NameASB2
Target SynonymsASB2Ankyrin repeat and SOCS box protein 2 antibody; ASB-2 antibodyFormLiquid
Species ReactivityHuman, Mouse, RatIsotypeIgG
Storage Buffer0.05% NaN3, 40% Glycerol., pH7.4 PBSPurification MethodAntigen affinity purified
ConjugateNon-conjugatedApplicationELISA, IHC
StorageUpon receipt

Immunogen Information


Immunogen DescriptionFusion protein of Human ASB2Target SpeciesHuman
Immunogen SequenceComplete sequences for the immunogen, target protein, and peptides are available upon request.Uniprot IDQ96Q27
Background Information
  • Uniprot Id

    Q96Q27

  • Target Species

    Human

  • Target Name

    ASB2

  • Target Full Name

    Ankyrin repeat and SOCS box protein 2

  • Target Function

    Substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Mediates Notch-induced ubiquitination and degradation of substrates including TCF3/E2A and JAK2. Required during embryonic heart development for complete heart looping. Required for cardiomyocyte differentiation.; Involved in myogenic differentiation and targets filamin FLNB for proteasomal degradation but not filamin FLNA. Also targets DES for proteasomal degradation. Acts as a negative regulator of skeletal muscle mass.; Targets filamins FLNA and FLNB for proteasomal degradation. This leads to enhanced adhesion of hematopoietic cells to fibronectin. Required for FLNA degradation in immature cardiomyocytes which is necessary for actin cytoskeleton remodeling, leading to proper organization of myofibrils and function of mature cardiomyocytes. Required for degradation of FLNA and FLNB in immature dendritic cells (DC) which enhances immature DC migration by promoting DC podosome formation and DC-mediated degradation of the extracellular matrix. Does not promote proteasomal degradation of tyrosine-protein kinases JAK1 or JAK2 in hematopoietic cells.

  • Target Subcellular Location

    Cytoplasm, cytoskeleton, stress fiber.; [Isoform 1]: Cytoplasm, myofibril, sarcomere, Z line.

  • Target Protein Families

    Ankyrin SOCS box (ASB) family

  • Target Tissue Specificity

    [Isoform 1]: Expressed in muscle cells.; [Isoform 2]: Expressed in hematopoietic cells.

  • Target Synonyms

    ASB2Ankyrin repeat and SOCS box protein 2; ASB-2

  • Target Background

    This gene encodes a member of the ankyrin repeat and SOCS box-containing (ASB) protein family. These proteins play a role in protein degradation by coupling suppressor of cytokine signalling (SOCS) proteins with the elongin BC complex. The encoded protein is a subunit of a multimeric E3 ubiquitin ligase complex that mediates the degradation of actin-binding proteins. This gene plays a role in retinoic acid-induced growth inhibition and differentiation of myeloid leukemia cells. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Inquire Rabbit anti-Human ASB2 Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification